MA50124A - Procédé de préparation de tubulysines et d'intermédiaires de celles-ci - Google Patents

Procédé de préparation de tubulysines et d'intermédiaires de celles-ci

Info

Publication number
MA50124A
MA50124A MA050124A MA50124A MA50124A MA 50124 A MA50124 A MA 50124A MA 050124 A MA050124 A MA 050124A MA 50124 A MA50124 A MA 50124A MA 50124 A MA50124 A MA 50124A
Authority
MA
Morocco
Prior art keywords
tubulysins
intermediaries
preparation
Prior art date
Application number
MA050124A
Other languages
English (en)
Inventor
Wendel Doubleday
Qingwu Jin
Kun-Liang Wu
Original Assignee
Seattle Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seattle Genetics Inc filed Critical Seattle Genetics Inc
Publication of MA50124A publication Critical patent/MA50124A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/021—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)n-C(=0)-, n being 5 or 6; for n > 6, classification in C07K5/06 - C07K5/10, according to the moiety having normal peptide bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
MA050124A 2017-09-08 2018-09-07 Procédé de préparation de tubulysines et d'intermédiaires de celles-ci MA50124A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762556234P 2017-09-08 2017-09-08

Publications (1)

Publication Number Publication Date
MA50124A true MA50124A (fr) 2020-07-15

Family

ID=63963374

Family Applications (1)

Application Number Title Priority Date Filing Date
MA050124A MA50124A (fr) 2017-09-08 2018-09-07 Procédé de préparation de tubulysines et d'intermédiaires de celles-ci

Country Status (15)

Country Link
US (2) US11389543B2 (fr)
EP (1) EP3679036A1 (fr)
JP (2) JP2020533308A (fr)
KR (1) KR20200051733A (fr)
CN (1) CN111601803A (fr)
AU (1) AU2018329951B2 (fr)
BR (1) BR112020004495A2 (fr)
CA (1) CA3073766A1 (fr)
EA (1) EA202090670A1 (fr)
IL (1) IL272837B2 (fr)
MA (1) MA50124A (fr)
MX (1) MX2020001928A (fr)
SG (1) SG11202001543XA (fr)
TW (1) TWI820038B (fr)
WO (1) WO2019051322A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI825169B (zh) * 2018-09-07 2023-12-11 美商思進公司 妥布賴森(tubulysins)及其中間體之製備之替代方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10230872A1 (de) 2002-07-09 2004-01-22 Morphochem AG Aktiengesellschaft für kombinatorische Chemie Verfahren zur Herstellung von substituierten Thiazol-2-ylmethylestern
EP3498289A1 (fr) 2005-07-07 2019-06-19 Seattle Genetics, Inc. Composés de monométhylvaline présentant des modifications de la chaîne latérale de phénylalanine au niveau de la terminaison c
MX2008015132A (es) 2006-05-30 2008-12-10 Genentech Inc Anticuerpos e inmunoconjugados y sus usos.
ES2649941T3 (es) 2007-02-23 2018-01-16 Aileron Therapeutics, Inc. Aminoácidos sustituidos para preparar péptidos macrocíclicos unidos a triazol
WO2008106080A2 (fr) * 2007-02-27 2008-09-04 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Synthèse de désacétoxytubulysine h et ses analogues
CN104379602B (zh) 2012-03-08 2017-05-03 哈洛齐梅公司 具有条件活性的抗表皮生长因子受体抗体及其使用方法
CN108465112B (zh) 2012-05-15 2022-04-29 西雅图基因公司 自稳定接头偶联物
WO2013173393A1 (fr) 2012-05-15 2013-11-21 Concortis Biosystems, Corp Conjugués médicamenteux, procédés de conjugaison et utilisations de ceux-ci
EP2708243A1 (fr) 2012-09-17 2014-03-19 OntoChem GmbH Molécules cytotoxiques liés à un ligand de récepteur
KR20160015227A (ko) 2013-05-31 2016-02-12 제넨테크, 인크. 항-세포벽 테이코산 항체 및 접합체
KR20160015286A (ko) 2013-05-31 2016-02-12 제넨테크, 인크. 항-세포벽 테이코산 항체 및 접합체
AU2015315007C1 (en) 2014-09-11 2021-06-03 Seagen Inc. Targeted delivery of tertiary amine-containing drug substances
CN107206101B (zh) * 2014-12-03 2021-06-25 基因泰克公司 季铵化合物及其抗体-药物缀合物
EA201791896A1 (ru) * 2015-02-25 2018-02-28 Уильям Марш Райс Юниверсити Дезацетокситубулизин н и его аналоги

Also Published As

Publication number Publication date
AU2018329951A1 (en) 2020-04-16
MX2020001928A (es) 2020-03-24
BR112020004495A2 (pt) 2020-09-08
EA202090670A1 (ru) 2020-07-28
IL272837B1 (en) 2024-02-01
CA3073766A1 (fr) 2019-03-14
US11389543B2 (en) 2022-07-19
JP2020533308A (ja) 2020-11-19
TWI820038B (zh) 2023-11-01
JP2023053386A (ja) 2023-04-12
WO2019051322A1 (fr) 2019-03-14
AU2018329951B2 (en) 2023-12-14
CN111601803A (zh) 2020-08-28
US20220323601A1 (en) 2022-10-13
TW201920128A (zh) 2019-06-01
KR20200051733A (ko) 2020-05-13
US20200297864A1 (en) 2020-09-24
SG11202001543XA (en) 2020-03-30
EP3679036A1 (fr) 2020-07-15
IL272837B2 (en) 2024-06-01
IL272837A (en) 2020-04-30

Similar Documents

Publication Publication Date Title
ZA202004025B (en) Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
MA52665A (fr) Procédé d'amélioration de l'expression de l'hémoglobine foetale
MA46479A (fr) Procédés et intermédiaires pour la préparation de nouveaux composés substitués de 6,7-dihydro-5h-benzo[7]annulène
GB201720163D0 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of hepatitis B
MA45798A (fr) Compositions et procédés d'inhibition de masp-3 pour le traitement de maladies et troubles divers
MA43835A (fr) Procédé de préparation de lieurs de médicaments pégylés et leurs intermédiaires
SG11202011296VA (en) Compositions and methods for the treatment of parkinson's disease
IL253999B (en) History of tetrahydrothiazepine in cyclics used to treat neoplastic and/or infectious diseases
MA53445A (fr) Procédés et compositions pour la modification de plantes
MA53370A (fr) Procédé et intermédiaires pour la préparation de bilastine
MA47511A (fr) Procédés de préparation d'ag-10, de ses intermédiaires et de sels correspondants
IL279397A (en) New compounds and their pharmaceutical preparations for the treatment of diseases
MA42497A (fr) Procédés et compositions pour la régulation sélective de l'expression protéique
MA51432A (fr) Procédé de préparation d'une amino-pyrimidine et de ses intermédiaires
IL270927B (en) fused 5,6 bicyclic compounds and compounds for the treatment of parasitic diseases
IL266926A (en) Compounds and methods for the treatment of oral infectious diseases
ZA202101489B (en) Compositions and methods for the treatment of parkinson's disease
MA50124A (fr) Procédé de préparation de tubulysines et d'intermédiaires de celles-ci
MA43178A (fr) Analogues d'épothilone, procédés de synthèse, procédés de traitement, et conjugués médicamenteux de ceux-ci
MA49555A (fr) Procédé amélioré de préparation d'imetelstat
HUE058259T2 (hu) Eljárás lubiproszton és annak intermedierei elkészítésére
EP3261446A4 (fr) Méthodes et compositions permettant le traitement ou la prévention de la maladie de parkinson
MA51510A (fr) Procédés de préparation de dérivés d'indolinobenzodiazépine
EP3773500A4 (fr) Compositions et procédés de détection et de traitement de la maladie d'alzheimer
ZA201801945B (en) Compositions and methods for the treatment of parkinson's disease